1 March 2013 in Journal of Neuro-Ophthalmology
Background: Acetazolamide is the mainstay of medical therapy for idiopathic intracranial hypertension (IIH). Its use in pregnant women has not been recommended because of reported teratogenic effects in rodents and rabbits. However, the safety of acetazolamide use during human pregnancy remains unclear. We report the pregnancy and offspring outcomes in women with intracranial hypertension (IH) treated with acetazolamide during pregnancy. Methods: Data were collected through questionnaires sent to patients with IH and their physicians. The questionnaires focused on IH diagnosis, obstetric history and outcomes, and pediatric outcomes. Results: A total of 101 women with IH were consented (total of 158 pregnancies) and acetazolamide usage before 13 weeks of gestation was reported in 50 pregnancies. The risk of spontaneous abortion was similar to the control group and no major complication was identified in the offspring of women treated with acetazolamide. Conclusion: There is no convincing evidence for an adverse effect for acetazolamide use in human pregnancy, even when prescribed prior to the 13th week of gestation. While the liberal use of acetazolamide should be avoided during pregnancy, this medication should remain a treatment option in pregnant women when clinically indicated.
14 October 2015 in Current Neurology and Neuroscience Reports
1 April 2019 in Multiple Sclerosis Journal – Experimental, Translational and Clinical
Background: Lipoic acid, an antioxidant, has beneficial effects in experimental acute optic neuritis and autoimmune encephalomyelitis. Optical coherence tomography can detect retinal nerve fiber layer thinning, representing axonal degeneration, approximately 3–6 months after acute optic neuritis. Objective: To determine whether lipoic acid is neuroprotective in acute optic neuritis. Methods: A single-center, double-blind, randomized, placebo controlled, 24-week trial. Intervention included 6 weeks of once daily lipoic acid (1200 mg) or placebo within 14 days of acute optic neuritis diagnosis. The primary outcome was the mean difference in affected eye retinal nerve fiber layer (RNFL) thickness from baseline to 24 weeks. Results: We enrolled 31 subjects (placebo n=16; lipoic acid n=15; average age 38.6 years (standard deviation (SD) 10.3)). Affected eye mean global RNFL thickness (µm) in the lipoic acid group decreased from 108.47 (SD 26.11) at baseline to 79.31 (SD 19.26) at 24 weeks. The affected eye RNFL in the placebo group decreased from 103.67 (SD 18.04) at baseline to 84.43 (SD 20.94) at 24 weeks. Unaffected eye RNFL thickness did not significantly change in either group over 24 weeks. Conclusion: Six weeks of oral lipoic acid supplementation after acute optic neuritis is safe and well tolerated; however, because of insufficient recruitment, we could not conclude that lipoic acid treatment was neuroprotective in acute optic neuritis.
31 August 2010 in Neurologic Clinics
15 September 2022 in American Journal of Ophthalmology Case Reports
To report the distinct pattern of retinal perfusion loss captured on optical coherence tomographic angiography (OCTA) in a case of compressive optic neuropathy associated with pituitary adenoma. A 51-year-old male had bitemporal hemianopia caused by a pituitary adenoma that compressed the optic chiasm. OCTA scans in both eyes showed peripapillary nerve fiber layer plexus defects in the nasal hemispheres and papillomacular corridors. On macular scans, the ganglion cell layer plexus showed papillomacular defects. The perfusion defects corresponded with thinning on structural OCT measurement and loss of sensitivity on visual field tests. Chiasm compression produces a characteristic pattern of perfusion loss that can be recognized OCTA. This knowledge may be useful in the diagnosis and classification of optic neuropathies.
1 December 2025 in Stroke
BACKGROUND: Retinal artery occlusion (RAO) is a form of ischemic stroke per the American Heart Association, yet high-level evidence guiding management and prognostication is limited. The risk of future cerebral infarction following nonarteritic isolated RAO (iRAO; without concomitant cerebral infarction) is unclear. This study compares the risk of stroke recurrence following iRAO versus nondisabling ischemic cerebrovascular events (NICEs), including transient ischemic attacks and minor ischemic strokes. METHODS: This was a retrospective cohort study using the 2016 to 2022 Nationwide Readmissions Database in the United States. Adults hospitalized primarily for RAO or NICE were included. Patients who were functionally dependent at discharge or had moderate to severe stroke (National Institutes of Health Stroke Scale score >4), arteritis or vasculitis, or RAO and concomitant cerebral infarction were excluded from the primary analysis. Two-to-one propensity score matching was performed to balance baseline characteristics between cohorts. The primary outcome was subsequent cerebral infarction within 300 days. Cox regression models and multivariable adjustments were used to estimate hazard ratios. RESULTS: A total of 1 673 145 patients hospitalized for nondisabling stroke, transient ischemic attack, or RAO were identified; 17 388 (1.0%) had RAO, of whom 4507 (25.9%) had concomitant cerebral infarction and were excluded for primary analyses. After applying additional exclusion criteria and propensity score matching, 11 185 patients with nonarteritic iRAO and 22 757 patients with NICE remained. Patients with iRAO had a significantly lower risk of subsequent cerebral infarction (hazard ratio, 0.26 [95% CI, 0.20–0.35]; P <0.001). Absolute cerebral infarction rates at 30, 90, and 180 days were lower in patients with iRAO versus patients with NICE (0.5% versus 2.3%, 0.8% versus 3.1%, and 1.2% versus 4.3%, respectively; all P <0.001 for all). CONCLUSIONS: Nonarteritic iRAO events were associated with significantly lower risks of subsequent cerebral infarction compared with NICE. These findings suggest that iRAO events are not equivalent to ischemic cerebrovascular events in terms of risk of subsequent stroke. Further studies are needed to optimize secondary stroke prevention strategies tailored to nonarteritic iRAOs.